NICE, the health technology appraisal institute for England and Wales, has issued final draft guidance recommending Novartis' VEGF-A inhibitor Lucentis (ranibizumab) as a treatment for visual impairment due to choroidal neovascularization secondary to pathological myopia.
NICE recommends it should only be prescribed if it is made available to the NHS as part of a patient...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?